Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 11.8% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,511,914 shares of the company's stock after acquiring an additional 476,245 shares during the period. Johnson & Johnson accounts for about 0.7% of Mitsubishi UFJ Asset Management Co. Ltd.'s portfolio, making the stock its 29th biggest position. Mitsubishi UFJ Asset Management Co. Ltd. owned about 0.19% of Johnson & Johnson worth $747,939,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds have also recently added to or reduced their stakes in the stock. Bernard Wealth Management Corp. bought a new position in shares of Johnson & Johnson in the 4th quarter valued at $36,000. Highline Wealth Partners LLC increased its stake in shares of Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after purchasing an additional 86 shares during the last quarter. von Borstel & Associates Inc. bought a new position in shares of Johnson & Johnson in the 1st quarter valued at $49,000. Harvest Fund Management Co. Ltd bought a new position in shares of Johnson & Johnson in the 1st quarter valued at $52,000. Finally, Capital A Wealth Management LLC bought a new position in shares of Johnson & Johnson in the 4th quarter valued at $50,000. Institutional investors own 69.55% of the company's stock.
Johnson & Johnson Trading Down 0.0%
NYSE JNJ opened at $170.72 on Thursday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $172.18. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The business's 50-day moving average price is $158.53 and its two-hundred day moving average price is $157.10. The firm has a market capitalization of $411.14 billion, a PE ratio of 18.26, a price-to-earnings-growth ratio of 2.17 and a beta of 0.41.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. The company had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same quarter in the prior year, the company earned $2.82 EPS. The firm's revenue for the quarter was up 5.8% compared to the same quarter last year. On average, analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.
Johnson & Johnson Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be given a dividend of $1.30 per share. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 3.0%. Johnson & Johnson's dividend payout ratio is presently 55.61%.
Analyst Ratings Changes
JNJ has been the topic of several recent analyst reports. Morgan Stanley lifted their price target on Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a research note on Thursday, July 17th. Barclays boosted their price objective on Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. Leerink Partnrs lowered Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Benchmark upgraded Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Finally, Wall Street Zen lowered Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research report on Friday, July 18th. Nine equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $174.50.
View Our Latest Stock Report on JNJ
Johnson & Johnson Company Profile
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
